



ASO Author Reflections: The FIBA Score—A Novel Scoring System to Predict Outcomes in Hepatocellular Carcinoma After Surgical Resection or Transarterial Chemoembolization

De-Hua Chang, MD¹, Yu-Dong Xiao, MD², and Yao Tong, MD²

¹Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany;

²Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, China

PAST

After curative resection, the prognosis for hepatocellular carcinoma (HCC) varies greatly, with a 30–70% 5-year survival rate. Likewise, the same can be said for patients with unresectable HCC treated with transarterial chemoembolization (TACE). To more accurately evaluate patient prognosis, several grading systems have been created. Most scoring systems only focus on a few aspects of this complex disease, resulting in a limited prognostic value.^{1,2} As a result, scoring systems are still not frequently used in clinical practice. Therefore, our goal was to create a scoring system that was simple to use and took into account the three key prognostic factors: liver function, systemic inflammation, and tumor features.

PRESENT

Our study included a training cohort to create a novel prognostic scoring system (named the function-inflammation-burden-alpha-fetoprotein [FIBA] score) and two validation cohorts to test its predictive value.³ The FIBA score is simple to use in clinical practice because it is made up of six commonly measured parameters: albumin, total bilirubin, lymphocyte count, α -fetoprotein (AFP) level, diameter of the largest tumor, and number of tumors. It has been demonstrated to be useful in detecting HCC patients

at high risk of having a poor outcome and can be used in patients who underwent curative surgical resection or TACE as the initial therapy.

In terms of prognostic predictive value, the FIBA score outperforms 16 other established scoring systems in both the training and validation cohorts.

FUTURE

In our Asian study cohort, the most common etiology for the development of HCC was chronic hepatitis B infection. Patients with alternative causes of HCC, such as chronic hepatitis C, alcoholic hepatitis, or non-alcoholic steatohepatitis, which is widespread in Western nations, have a different prognosis. Patients receiving systemic therapy were also excluded from our study. Here, additional validation of the FIBA score is required to support our findings and permit broader applicability.

FUNDING Open Access funding enabled and organized by Projekt DEAL.

DISCLOSURES De-Hua Chang, Yu-Dong Xiao, and Yao Tong declare no conflicts of interest.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright

© The Author(s) 2022

First Received: 6 December 2022

Accepted: 6 December 2022

Published Online: 24 December 2022

D.-H. Chang, MD

e-mail: De-Hua.Chang@med.uni-heidelberg.de

holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

REFERENCES

1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol*. 2022;76:681–93.
2. Kok B, Abraldes JG. Child-Pugh classification: time to abandon? *Semin Liver Dis*. 2019;39:96–103.
3. Tong Y, Chang DH, Wang LZ, et al. An integrated liver function, systemic inflammation, and tumor characteristic score predicts prognosis in hepatocellular carcinoma after curative resection. *Ann Surg Oncol*. 2022. <https://doi.org/10.1245/s10434-022-12899-x>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.